
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
San Diego-A newer bulking agent consisting of synthetic calcium hydroxylapatite compares favorably with traditional glutaraldehyde cross-linked bovine collagen as a treatment for type III stress urinary incontinence or intrinsic sphincteric deficiency, according to an interim analysis of data from an ongoing randomized trial of the two substances.





